Analysts Estimates and Ratings Franklin Resources, Inc.(NYSE:BEN) and Amicus Therapeutics, Inc.(NASDAQ:FOLD)

0
12

Franklin Resources, Inc. (BEN) will report its next earnings on Jan 29 BMO. The company reported the earnings of $1.13/Share in the last quarter where the estimated EPS by analysts was $0.74/share. The difference between the expected and actual EPS was $0.39/share, which represents an Earnings surprise of 52.7%.

Many analysts are providing their Estimated Earnings analysis for Franklin Resources, Inc. and for the current quarter 13 analysts have projected that the stock could give an Average Earnings estimate of $0.72/share. These analysts have also projected a Low Estimate of $0.63/share and a High Estimate of $0.75/share.

In case of Revenue Estimates, 8 analysts have provided their consensus Average Revenue Estimates for Franklin Resources, Inc. as 1.49 Billion. According to these analysts, the Low Revenue Estimate for Franklin Resources, Inc. is 1.47 Billion and the High Revenue Estimate is 1.52 Billion. The company had Year Ago Sales of 1.62 Billion.

These analysts also forecasted Growth Estimates for the Current Quarter for BEN to be -19.3%. They are projecting Next Quarter growth of -14.1%. For the next 5 years, Franklin Resources, Inc. is expecting Growth of 3.7% per annum, whereas in the past 5 years the growth was -13.79% per annum.

Some buy side analysts are also providing their Analysis on Franklin Resources, Inc., where 0 analysts have rated the stock as Strong buy, 1 analysts have given a Buy signal, 2 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for Franklin Resources, Inc. might touch $33 high while the Average Price Target and Low price Target is $28.82 and $23 respectively.

Franklin Resources, Inc. closed its last trading session at $30.32 with the gain of 0.49%. The Market Capitalization of the company stands at 15.4 Billion. The Company has 52-week high of $42.29 and 52-week low of $27.34. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 1.76% where SMA50 and SMA200 are -1.99% and -5.23% respectively. The Company Touched its 52-Week High on 01/24/18 and 52-Week Low on 12/26/18.

The Relative Volume of the company is 0.85 and Average Volume (3 months) is 4.22 million. The company’s P/E (price to earnings) ratio is 9.46 and Forward P/E ratio of 10.77.

The company shows its Return on Assets (ROA) value of 4.5%. The Return on Equity (ROE) value stands at 7.2%. While it’s Return on Investment (ROI) value is 15.2%.

While looking at the Stock’s Performance, Franklin Resources, Inc. currently shows a Weekly Performance of 3.99%, where Monthly Performance is -4.93%, Quarterly performance is -0.29%, 6 Months performance is -5.2% and yearly performance percentage is -24.16%. Year to Date performance value (YTD perf) value is 2.73%. The Stock currently has a Weekly Volatility of 2.41% and Monthly Volatility of 3.22%.

Amicus Therapeutics, Inc. (FOLD) will report its next earnings on Feb 04 BMO. The company reported the earnings of $-0.84/Share in the last quarter where the estimated EPS by analysts was $-0.28/share. The difference between the expected and actual EPS was $-0.56/share, which represents an Earnings surprise of -200%.

Many analysts are providing their Estimated Earnings analysis for Amicus Therapeutics, Inc. and for the current quarter 7 analysts have projected that the stock could give an Average Earnings estimate of $-0.29/share. These analysts have also projected a Low Estimate of $-0.3/share and a High Estimate of $-0.26/share.

In case of Revenue Estimates, 6 analysts have provided their consensus Average Revenue Estimates for Amicus Therapeutics, Inc. as 29.91 Million. According to these analysts, the Low Revenue Estimate for Amicus Therapeutics, Inc. is 28.32 Million and the High Revenue Estimate is 32.5 Million. The company had Year Ago Sales of 14.73 Million.

These analysts also forecasted Growth Estimates for the Current Quarter for FOLD to be 31.7%. They are projecting Next Quarter growth of 7.14%. For the next 5 years, Amicus Therapeutics, Inc. is expecting Growth of 46.86% per annum, whereas in the past 5 years the growth was 40.07% per annum.

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for Amicus Therapeutics, Inc. might touch $31 high while the Average Price Target and Low price Target is $18.22 and $12 respectively.

Amicus Therapeutics, Inc. closed its last trading session at $11.48 with the gain of 3.05%. The Market Capitalization of the company stands at 2.24 Billion. The Company has 52-week high of $17.62 and 52-week low of $8.27. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 17.81% where SMA50 and SMA200 are 12.88% and -11.21% respectively. The Company Touched its 52-Week High on 06/20/18 and 52-Week Low on 12/24/18.

The Relative Volume of the company is 0.72 and Average Volume (3 months) is 2.77 million. The company’s P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0.

The company shows its Return on Assets (ROA) value of -43%. The Return on Equity (ROE) value stands at -73.6%. While it’s Return on Investment (ROI) value is -54%.

While looking at the Stock’s Performance, Amicus Therapeutics, Inc. currently shows a Weekly Performance of 14.52%, where Monthly Performance is 11.5%, Quarterly performance is -7.87%, 6 Months performance is -28% and yearly performance percentage is -16.75%. Year to Date performance value (YTD perf) value is 23.49%. The Stock currently has a Weekly Volatility of 7.00% and Monthly Volatility of 6.82%.

SHARE